MedTrace Logo

Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

NCT06634160 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-02-06

No results posted yet for this study

Summary

The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.

Conditions

  • Heterozygous Familial Hypercholesterolemia

Interventions

DIAGNOSTIC_TEST

Fibroscan

Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).

OTHER

Sample collection

20 mL whole blood sample

Sponsors & Collaborators

  • University Hospital, Angers

    collaborator OTHER_GOV

  • Rennes University Hospital

    collaborator OTHER

  • Nantes University Hospital

    lead OTHER

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2027-01-30
Completion
2028-01-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06634160 on ClinicalTrials.gov